跳至主要内容
临床试验/NCT04590768
NCT04590768已完成不适用

Tolerance of Regular Meal Intake With Mycoprotein

Wageningen University and Research2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2020年10月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
2
主要终点
Change in gastro intestinal (GI) complaints

研究概览

简要总结

This study aims to assess the impact of daily intake of 11 grams of Fermotein™ on gastrointestinal complaints and several other health related biomarkers. Furthermore, consumer acceptance is investigated. The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with fermotein based meals and a 18-day intervention with control meals. At the start and at the end of the intervention, a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

详细描述

Fermotein™ is a mycoprotein, derived from fungi, especially produced for human consumption. It is high in protein, high in fiber, low in saturated fat and contains no cholesterol. Its functional properties and nutrient content makes them ideal to use as an ingredient for meat alternatives and other vegetarian/vegan food products. This study aims to assess the impact of frequent intake of 11 grams of Fermotein™ powder (dry) on gastrointestinal complaints and several other health related biomarkers.

The primary objective is to investigate gastro-intestinal complaints during 18 days of Fermotein™ consumption. The secondary objective is to assess blood based parameters related to general health and consumer acceptance.

The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with Fermotein™ based meals and a 18-day intervention with control meals. At the start and at the end of the intervention a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change in gastro intestinal (GI) complaints

时间窗: Daily, during 18 days of Fermotein™ intake and up to three days after intake.

Determined by combining multiple outcome measures ( bloated feeling, belching, abdominal pain, flatulence, nausea, diarrhoea, constipation) measured via questionnaires with Visual Analogue Scale (VAS) scores; from no complaints (minimal) to serious complaints (maximum). Higher values represent a worse outcome.

次要结局

  • change in blood hemoglobin(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood ferritin(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood cholesterol (total)(before and after 18 days consumption of Fermotein™ or control product)
  • change in blood glucose(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood ASAT(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood leukocyte cell counts(at baseline, and after 18 days of fermotein or control product consumption)
  • change in blood insulin(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood pressure(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood Fe (iron)(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood ALAT(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood GGT(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood creatinine(at baseline, and after 18 days of Fermotein™ or control product consumption)
  • change in blood zonulin(at baseline, and after 18 days of Fermotein™ or control product consumption)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Diederik Esser

Principle Investigator

Wageningen University and Research

研究点 (2)

Loading locations...

相似试验